Agilent Technologies and National Cancer Centre Singapore Enter into Research Collaboration Agreement
Tuesday, September 19, 2023
Agilent Technologies signed a research collaboration agreement with the National Cancer Centre Singapore (NCCS) to accelerate a step forward in the field of translational cancer research, particularly in the context of Asian-prevalent cancers.
Over the next two years, this partnership aims to expedite progress in understanding the genomic landscape of cancers that are prevalent in Asian populations. This agreement seeks to fast-track advancements in unravelling the genomic characteristics of cancer types that have a high prevalence among Asian populations.
Agilent's automated NGS library preparation platform at Singapore's Cancer Discovery Hub (CDH) aims to simplify the analysis of multiple genes and complex genetic abnormalities within genomic DNA, ensuring consistent and reproducible results.
This research focuses on improving the understanding of tumour genomes and harnessing this information to enhance patient care. Ultimately, the platform's deployment has the potential to revolutionise clinical trials, diagnostics, and treatment decisions in oncology.
The goal of this collaboration is to translate these findings into practical applications for patient care. This includes improving the accuracy and effectiveness of clinical trials and diagnostics in the field of oncology, as well as enhancing the decision-making process for treatment strategies. Moreover, this partnership will accelerate the development of next-generation diagnostic tools, ultimately reshaping the landscape of patient care in cancer.
